Warning letter
Abrams Royal Pharmacy: warning letter of Jul 14, 2014
FDA warning letter 428466 · Dallas District Office
Key facts
| Reference number | 428466 |
|---|---|
| Company | Abrams Royal Pharmacy |
| Subject | Compounding Pharmacy/Adulteration/Misbranding |
| Issue date | Jul 14, 2014 |
| Posted date | Jul 28, 2014 |
| Issuing office | Dallas District Office |
| Product type | Drugs |
| CFR sections cited | 210.1(b), 201.115, 211, 200.10(b), 211.28(a), 211.42(b), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.113(b), 211.166(a) |
| Inspection city | Dallas |
| Inspection ZIP | 75231 |
| Inspection start date | Dec 12, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: